BEAM insider transaction filings
Beam Therapeutics Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-29. Screen BEAM transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-29 | 4 | Simon Amy — Chief Medical Officer | Sale (S): 16,667 @ $25.74 | EDGAR |
| 2026-07-02 | 4 | Simon Amy — Chief Medical Officer | Sale (S): 373 @ $34.73 | EDGAR |
| 2026-07-01 | 4 | Evans John M. — CEO, Director | Option exercise (M): 18,663 @ $0.67 · Option exercise (M): 6,337 @ $1.03 · Sale (S): 13,421 @ $35.13 · Sale (S): 11,579 @ $35.91 · Option exercise (M): 25,000 @ $1.03 · Sale (S): 23,100 @ $34.26 · +4 more | EDGAR |
| 2026-06-29 | 4 | FMR LLC — 10% owner | Sale (S): 33,372 @ $35.12 · Sale (S): 251,488 @ $35.26 | EDGAR |
| 2026-06-22 | 4 | Ciaramella Giuseppe — President | Option exercise (M): 6,505 @ $0.67 · Option exercise (M): 29,000 @ $1.03 · Option exercise (M): 6,505 (derivative) @ $0 · Option exercise (M): 29,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Fishman Mark — Director | Grant/award (A): 19,676 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Guindo Chirfi — Director | Grant/award (A): 19,676 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Shaw Christi — Director | Grant/award (A): 19,676 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Walsh Kathleen E — Director | Grant/award (A): 19,676 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | COOPER GRAHAM K — Director | Grant/award (A): 19,676 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | MARAGANORE JOHN — Director | Grant/award (A): 19,676 (derivative) @ $0 | EDGAR |
| 2026-04-06 | 4 | Evans John M. — CEO, Director | Sale (S): 30,078 @ $24.58 | EDGAR |
| 2026-04-06 | 4 | Simon Amy — Chief Medical Officer | Sale (S): 6,700 @ $24.58 | EDGAR |
| 2026-04-06 | 4 | Cavanagh Bethany J — SVP, Finance and Treasurer | Sale (S): 3,242 @ $24.58 | EDGAR |
| 2026-04-06 | 4 | Bellon Christine — Chief Legal Officer | Sale (S): 5,956 @ $24.58 | EDGAR |
| 2026-04-06 | 4 | Ciaramella Giuseppe — President | Sale (S): 11,810 @ $24.58 | EDGAR |
| 2026-04-02 | 4 | Bellon Christine — Chief Legal Officer | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2026-04-02 | 4 | Cavanagh Bethany J — SVP, Finance and Treasurer | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2026-04-02 | 4 | Simon Amy — Chief Medical Officer | Grant/award (A): 31,750 @ $0 | EDGAR |
| 2026-04-02 | 4 | Emany Sravan Kumar — Chief Financial Officer | Grant/award (A): 31,750 @ $0 | EDGAR |
| 2026-04-02 | 4 | Ciaramella Giuseppe — President | Grant/award (A): 40,000 @ $0 | EDGAR |
| 2026-04-01 | 4 | Evans John M. — CEO, Director | Option exercise (M): 25,000 @ $0.67 · Sale (S): 25,000 @ $22.37 · Option exercise (M): 25,000 @ $0.67 · Sale (S): 25,000 @ $22.76 · Grant/award (A): 90,000 @ $0 · Option exercise (M): 25,000 (derivative) @ $0 · +1 more | EDGAR |
| 2026-02-26 | 4 | Ciaramella Giuseppe — President | Option exercise (M): 35,000 @ $17 · Sale (S): 35,000 @ $32.00 · Option exercise (M): 35,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Ciaramella Giuseppe — President | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Cavanagh Bethany J — SVP, Finance and Treasurer | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Emany Sravan Kumar — Chief Financial Officer | Grant/award (A): 63,500 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Bellon Christine — Chief Legal Officer | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Evans John M. — CEO, Director | Option exercise (M): 19,336 @ $0.67 · Option exercise (M): 5,664 @ $0.67 · Sale (S): 16,333 @ $29.19 · Sale (S): 8,667 @ $29.74 · Option exercise (M): 25,000 @ $0.67 · Sale (S): 22,094 @ $28.27 · +5 more | EDGAR |
| 2026-02-02 | 4 | Simon Amy — Chief Medical Officer | Grant/award (A): 88,500 (derivative) @ $0 | EDGAR |
| 2026-01-26 | 4 | Cavanagh Bethany J — SVP, Finance and Treasurer | Sale (S): 6,198 @ $35.00 | EDGAR |
| 2026-01-26 | 4 | Bellon Christine — Chief Legal Officer | Sale (S): 1,371 @ $34 | EDGAR |
| 2026-01-21 | 4 | Cavanagh Bethany J — SVP, Finance and Treasurer | Sale (S): 3,034 @ $30.12 | EDGAR |
| 2026-01-20 | 4 | Bellon Christine — Chief Legal Officer | Sale (S): 2,111 @ $33.62 · Sale (S): 15,959 @ $34.72 · Sale (S): 559 @ $35.40 | EDGAR |
| 2026-01-05 | 4 | Emany Sravan Kumar — Chief Financial Officer | Sale (S): 6,294 @ $27.10 | EDGAR |
| 2026-01-05 | 4 | Bellon Christine — Chief Legal Officer | Sale (S): 1,254 @ $27.10 | EDGAR |
| 2026-01-05 | 4 | Simon Amy — Chief Medical Officer | Grant/award (A): 12,500 @ $0 | EDGAR |
| 2025-10-29 | 4 | FMR LLC — 10% owner | Sale (S): 459 @ $26.68 | EDGAR |
| 2025-10-08 | 4 | FMR LLC — 10% owner | Gift (G): 1,232,434 @ $0 | EDGAR |
| 2025-10-03 | 4 | Cavanagh Bethany J — SVP, Finance and Treasurer | Sale (S): 467 @ $24.53 | EDGAR |
| 2025-10-03 | 4 | Bellon Christine — Chief Legal Officer | Sale (S): 373 @ $24.53 | EDGAR |
| 2025-10-03 | 4 | Evans John M. — CEO, Director | Option exercise (M): 25,000 @ $0.67 · Sale (S): 25,000 @ $24.51 · Option exercise (M): 25,000 @ $0.67 · Sale (S): 25,000 @ $24.63 · Option exercise (M): 25,000 (derivative) @ $0 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2025-08-01 | 4 | FMR LLC — 10% owner | Sale (S): 48,374 @ $20.50 | EDGAR |
| 2025-07-03 | 4 | Simon Amy — Chief Medical Officer | Sale (S): 374 @ $16.94 · Sale (S): 876 @ $20.12 | EDGAR |
| 2025-06-06 | 4 | Fishman Mark — Director | Grant/award (A): 33,662 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Ho Carole — Director | Grant/award (A): 33,662 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Guindo Chirfi — Director | Grant/award (A): 33,662 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Shaw Christi — Director | Grant/award (A): 33,662 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Walsh Kathleen E — Director | Grant/award (A): 33,662 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | COOPER GRAHAM K — Director | Grant/award (A): 33,662 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | MARAGANORE JOHN — Director | Grant/award (A): 33,662 (derivative) @ $0 | EDGAR |
Recent 8-K events — Beam Therapeutics Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-08 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-05 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2026-02-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-11 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets | EDGAR |
| 2025-11-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BEAM returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →